MAINZ, Germany, and SHANGHAI, China, Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma” or “Group”; Stock Symbol: 600196.SH, 02196.HK), today announced that the first 72 participants have already been dosed with BNT162b1 following IND approval by the Chinese regulatory authority, National Medical Products Administration (NMPA). BioNTech and Fosun Pharma are jointly developing the COVID-19 vaccine candidate in China. The trial is part of BioNTech’s global development program aimed at supporting a global supply upon regulatory approval. ============= BEIJING (Reuters) - China has approved an early-stage trial in humans of German firm BioNTech's 22UAy.FBNTX.O experimental COVID-19 vaccine, its local partner Shanghai Fosun Pharmaceutical 600196.SS2196.HK said on Thursday. ============= 看來是中德合作的疫苗,而且人體試驗在對岸做的 東洋看來是要逆時鐘阿